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ABSTRACT 
INTRODUCTION 
            Coronary artery disease is now the most common cause of death and 
disability. Vitamin D deficiency is recently being associated with endothelial 
dysfunction, acute coronary syndromes and other cardiovascular risk factors such 
as diabetes and hypertension. Considering the growing burden of cardiovascular 
morbidity and mortality, there is an urgent need to study this association as 
Vitamin D deficiency is an easily detectable and correctable risk factor. 
AIM OF THE STUDY 
           To study the correlation of low serum 25(OH) vitamin D levels as a risk 
factor for Myocardial Infarction. 
MATERIALS AND METHODS 
          A total of 100 patients were included in our study which was an 
observational case control study. Based on the inclusion and exclusion criteria, we 
selected 50 cases of acute myocardial infarction who were admitted in the 
Intensive Coronary Care Unit at our hospital. We excluded the patients who had 
diabetes, hypertension and prior cardiac disease. The control group included 50 
healthy age and sex matched individuals. The serum levels of 25(OH) Vitamin D 
was assessed in each of these patients and analyzed for the presence of statistical 
significance. 
OBSERVATION AND RESULTS  
         We found a positive correlation between low Vitamin D levels < 15ng/ml and 
the occurrence of first cardiovascular event in the patients admitted with acute 
myocardial infarction (p = 0.001). We also found a strong association between low 
Vitamin D levels and body mass index > 25 kg/m
2
 (p = 0.006). The mean Vitamin 
D level in young patients < 40yrs of age with myocardial infarction was very low 
(mean = 9.58 ng/ml) when compared to the controls and those > 40yrs of age. 
There was no significant association between the Vitamin D status and other 
variables such as age, gender, lipid profile or serum calcium levels.  
CONCLUSION 
        In this study, there was significant correlation between Vitamin D deficiency 
and coronary artery disease. BMI > 25 kg/m
2
 was found to be associated with low 
Vitamin D levels thereby aggravating the occurrence of cardiovascular events in 
obese individuals. Hence, the early detection and management of Vitamin D 
deficiency is essential to prevent adverse cardiovascular events.  
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INTRODUCTION 
INTRODUCTION 
 
Cardiovascular diseases are the commonest cause of mortality and  
morbidity worldwide.
1
 The prevalence of cardiovascular disease has rapidly 
increased in the past few years. Though there are many well established risk 
factors for cardiovascular disease, emerging novel risk factors are being assessed 
by various epidemiological studies and continue to be an important aspect of 
debate regarding their nature of association and the role they play in reducing death 
and disability due to cardiovascular disease. 
Over the recent years, there has been much emphasis and research over one 
such risk factor i.e. Vitamin D Deficiency which is now attracting importance from 
many medical and nutritional communities as knowledge emerges of its biological 
function and its association with decreased risk of many chronic diseases. 
          Hypovitaminosis D is a worldwide health problem. In addition to its well 
defined role as a major regulator of bone and calcium metabolism, several studies 
have found associations of poor Vitamin D status with coronary artery calcification 
and heart failure, as well as positive correlation with hypertension, diabetes 
mellitus, metabolic syndrome, atherosclerosis, peripheral arterial disease, cancer 
and many autoimmune disorders. 
          Vitamin D deficiency has been linked to an increased risk of Coronary 
Artery Disease (CAD) and cardiovascular (CV) death. Endothelial dysfunction 
plays a vital role in the pathogenesis of Coronary Artery Disease and Vitamin D 
deficiency is postulated to promote endothelial dysfunction. Following the 
discovery of the expression of Vitamin D receptors and 1α hydroxylase in the 
myocardium and endothelium, several biological mechanisms that link Vitamin D 
with CAD and its risk factors have been identified. Vitamin D mainly acts through 
its role in maintaining calcium homeostasis and gene transcription to prevent 
cardiovascular diseases and its risk factors. 
                      
Many data have shown that cardiovascular morbidity and mortality are 30-
50% more in the regions of less sun exposure due to season or latitude and that 
mortality from CAD is  highest in winter. All these studies point to a causal 
association of Vitamin D, as its serum levels reduces in people who live away from 
the equator because of reduced exposure to ultraviolet rays. The prevalence of 
Vitamin D deficiency is even higher in dark skinned people and elderly persons. 
Many studies worldwide have confirmed that myocardial infarction patients 
have lower Vitamin D levels than control subjects. It was postulated that those 
with low Vitamin D levels had almost 60% higher risk of myocardial infarction 
than those with the highest levels.  
In spite of the rising proportions of CAD in Asians, only limited data are 
available on the relationship between Vitamin D, CAD and endothelial 
dysfunction. Though numerous epidemiological studies have found significant 
association of Vitamin D deficiency with several cardiovascular risk factors like 
Diabetes, Hypertension and Dyslipidemia, the occurrence of Vitamin D deficiency 
itself as an independent risk factor for cardiovascular mortality is still disputed. 
Since Vitamin D deficiency can be easily measured and treated, trials to study the 
effect of hypovitaminosis D and its supplementation to prevent and treat 
cardiovascular diseases are currently considered important areas of research. 
The increasing rate of coronary artery disease and the associated morbidity 
and mortality make it necessary to develop further research in this study 
population. Many studies have been done and many are going on to assess the 
Vitamin D status in these patients. A practical time to check for 25(OH) Vitamin D 
deficiency and to start treatment is at the time of an acute myocardial infarction. 
Hence this study was designed to determine whether the presence of 
Hypovitaminosis D has significant correlation with Coronary Artery Disease. 
      
 
 
 
  
 
 
 
 
 AIMS AND OBJECTIVES 
  
AIM OF THE STUDY 
1. The primary aim of our study was to assess the serum levels of 25(OH) 
Vitamin D in patients with Acute ST Elevation Myocardial Infarction and to 
compare their levels with that of age and sex matched controls. 
2. To study if there is a causal association of Vitamin D deficiency as an 
independent risk factor for Coronary Artery Disease. 
3. The secondary objectives were :   
i) To study the prevalence of Vitamin D deficiency in our study 
population and to assess the severity. 
ii) To identify whether any association exists between age, gender, body 
mass index, total cholesterol, triglyceride and calcium with serum 
levels of Vitamin D. 
iii) To study the lipid profile, body mass index and serum calcium in the 
cases and compare them with the controls.  
 
 
 
 
  
 
 
 
 
 
 
           REVIEW OF 
LITERATURE 
REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
The first documented description of a patient with an acute coronary 
syndrome is in the Ebers papyrus from 2600 BC, which states, “If you find a man 
with heart discomfort, with pain in his arms, at the side of his heart, death is near.” 
The description is still apt, but the prognosis has changed over the centuries.  
The origin of the current epidemic of cardiovascular disease can be traced 
back to the time of industrialization in the 1700s. The three factors largely 
responsible for this were an increase in the use of tobacco products, reduced 
physical activity and the adoption of a diet high in fat, calories and cholesterol. 
Although the clinical syndrome of angina was described in the 1770s, it was not 
until 1912 that James B. Herrick described Acute Myocardial Infarction (MI). 
DEFINITIONS
4
 
The term „Acute Coronary Syndromes’ describes a spectrum of clinical 
syndromes that are divided into those with ST elevation or new left bundle branch 
block and those with unstable angina and non ST elevation MI. 
          Acute MI is defined as a rise and/or fall in cardiac biomarkers with at least 
one value above the 99
th
 percentile of the upper reference limit, along with 
evidence of ischemia. Established MI is defined by any one of the following i.e. 
development of new pathologic Q waves on serial ECGs, imaging evidence of MI 
or pathologic findings of healed or healing MI. 
Ischemia is defined as any symptoms of ischemia, ECG changes suggestive 
of new ischemia, development of pathologic Q waves or imaging evidence of 
infarction. 
The term unstable angina describes a syndrome that is intermediate between 
chronic stable angina and MI. It is a clinical diagnosis based on a history of chest 
pain and exclusion of the diagnosis of MI by electrocardiography (ECG) or cardiac 
enzyme testing. 
An occlusive thrombus can lead to an acute ST-segment elevation MI which 
denotes a full thickness (subendocardial to subepicardial) myocardial ischemia 
unless the subtended myocardium is richly collateralized. On the other hand, the 
thrombus formed may not be occlusive, but rather mural, and the patient may 
develop unstable angina or non ST segment elevation changes on the ECG such as 
ST depression or T wave changes. 
INCIDENCE & SIGNIFICANCE 
  
 
 As per the World Health Report,
1
 by the year 2020, cardiovascular diseases ( 
CVD ) will be the leading cause of mortality and morbidity in India.
 
With demographic shifts, epidemiological transition and increasing 
urbanization are associated with an increase in CVD risk factors such as smoking, 
sedentary lifestyle, obesity, hypertension and hypercholesterolemia. Mortality data 
from CVD in India were also reported by the World Health Organization. The 
Global Status on Non-Communicable Diseases Report (2011) has reported that 
there were more than 2.5 million deaths from CVD in India in 2008, two-thirds due 
to Coronary Heart Disease (CHD) and one-third due to stroke. Sub-analysis of the 
mortality trends shows that CHD mortality is higher in the south Indian states 
while stroke mortality is higher in the eastern Indian states.
2
 
 
Morbidity - Disability  adjusted life years (DALYs) lost from Coronary 
Heart Diseases in India are expected to double from the year 2000 to 2020 in both 
men and women to 7.7 million and 5.5 million, respectively.
2
 In the last 50 years 
there have been multiple cardiovascular epidemiological studies in India that have 
defined prevalence of CHD and stroke and identified the burden of disease.
    
  
    
Proportional Mortality Rates for all ages in India 
 
Proportion of Non Communicable Disease (NCD) deaths < 70yrs age 
 
 
 
Annual Non Communicable Disease deaths are predicted to increase 
immensely to 52 million in 2030. Annual cardiovascular disease mortality is 
expected to increase by 6 million.
2
 
 
Studies in the middle of the last century reported a low prevalence of 1%-2% 
in urban locations and 0.5%-1% in rural locations with very little urban-rural 
Cardiovascular diseases - 39% 
Cancer - 27% 
Diabetes - 4%   
Others - 30% 
difference. In the intervening years the CHD prevalence in urban areas increased to 
10%-12% while it increased to 4%-5% in rural areas.
2
 
             Urban India has high prevalence of coronary heart disease (8%-10%). It 
has been estimated that around 30 million people (14.1 million in urban areas and 
15.7 million in rural areas) are suffering from CAD in India. Moreover, CAD 
occurs a decade sooner in India when compared to the west.
51 
Cardiovascular mortality data from India has reported large regional 
variations with annual mortality rates greater than 250/100,000 in southern and 
eastern regions of the country and less than 100/100,000 in central India.
2  
There 
are large urban-rural differences in cardiovascular mortality also, with rates of less 
than 200/100,000 in rural areas and 450-500/100,000 in metropolitan urban 
locations.
 
 
The higher prevalence of cardiovascular risk factors in urban areas in India 
is in contrast to high income countries where the CVD risk factors are equal in 
urban and rural areas.
 
 
  
PATHOPHYSIOLOGY 
The syndromes of unstable angina, non ST elevation MI and ST elevation 
MI are a continuum and the path physiology is heterogeneous and dynamic. The 
clinical presentation depends on the severity of the arterial injury, the size and type 
of thrombus formed, the extent and duration of ischemia and the amount of 
previous myocardial necrosis. The extent of ischemia depends on the myocardial 
distribution of the ischemia producing artery, the severity of the ischemia 
producing stenosis, the absence or presence of collateral circulation, factors that 
affect the supply of oxygenated blood and increased myocardial demands, 
including the heart rate, blood pressure and contractility. 
The five major causes of acute coronary syndromes are thrombus, 
mechanical obstruction, dynamic obstruction, inflammation and increased organ 
demand.
4 
The major pathophysiologic mechanism is rupture or fissuring of an 
atheromatous plaque with superimposed thrombus. Superficial fissuring of a 
plaque usually results in platelet deposition, but there is less superimposed 
thrombus formation in patients with unstable angina than in those with Q wave MI, 
which is usually associated with deep arterial injury and occlusive thrombus. 
The atheromatous plaque develops in the following way: 
 Damage occurs in the endothelium due to hypertension, diabetes, smoking 
or dyslipidemia. 
 Monocytes approach these affected areas and transform into macrophages 
that cause local inflammation by releasing cytokines. 
 Macrophages accumulate oxidized fat to form a fatty streak. 
 The fatty deposits and white blood cells grow and send signals to smooth 
muscle cells in the media to divide and multiply. As a result, the lesion 
begins to stick out into the lumen. 
Atheromatous plaque formation 
                                              
 
 Blood platelets can accumulate and form clots on the irregular surface of the 
plaque. The clot can remain there and clog the artery, or break off and lodge 
in a smaller artery, completely closing off blood flow beyond it resulting in 
tissue necrosis. 
 As the atheroma progresses, calcification of the plaque occurs. 
 Angioscopic findings show that the thrombus associated with unstable 
angina is white or gray and consists mostly of platelets whereas the thrombus in 
patients with acute MI consists mostly of red blood cells.  
 
Vascular pathology and Coronary syndromes 
 
 
Loss of integrity of the arterial wall and platelet thrombus, with cessation of 
coronary blood flow through the infarct related artery, thus drives myocardial 
ischemia and injury. As described by Reimer and Jennings, the wavefront of 
necrosis extends from the subendocardium to the subepicardium.
4
 
The extent of necrosis varies as a function of collateral flow, the length of 
time that coronary blood flow has halted and the extent of diminution of coronary 
blood flow. 
RISK FACTORS 
The four major risk factors of CHD are hypertension, dyslipidemia, 
diabetes and smoking. These risk factors can act independently or in a synergistic 
way to promote atherosclerosis. 
The INTERHEART study was conducted among South Asians to study the 
cardiovascular risk factors.
3
 
 
 
             The INTERHEART study showed that apoA/apoB ratio and smoking 
constituted for 67% of the total Population Attributable Risk (PAR). 
9 simple risk factors accounted for 90% of PAR in men and women. These 
risk factors are smoking, Diabetes, Hypertension, Waist Hip Ratio, Diet, Physical 
activity, Alcohol intake, apolipoprotein and psychosocial factors. 
The CUPS (Chennai Urban Population Study) showed that in urban areas, 
the prevalence of cardiovascular risk factors were significantly higher in the low 
income groups when compared with the middle income groups.
2
 
 
 
Major cardiovascular risk factors indicated in JNC-7 report are: 
 
 Hypertension 
 Smoking 
 Obesity 
 Physical inactivity 
 Diabetes mellitus 
 Dyslipidemia 
 Microalbuminuria or estimated GFR< 60 ml/min 
 > 55 yrs for men, 
 > 65 yrs for women 
 Family history of premature cardiovascular disease 
 < 55 yrs for men 
 < 65 yrs for women. 
ACUTE MYOCARDIAL INFARCTION 
             Based on the ECG, acute MI may be broadly classified as ST Elevation MI 
(STEMI) or Non ST Elevation MI (NSTEMI). Since the pathophysiology in both 
the types is similar there is considerable overlap in acute coronary syndromes with 
respect to the ultimate outcome. However, the recognition of STEMI is important 
because it mandates the need for urgent reperfusion therapy.        
 
 
Age and Sex adjusted incidence rates of acute MI from 1999 to 2008.
89
 
Community incidence rates for STEMI have declined over the past decade, 
whereas those for non ST elevation MI have increased. 
4 
Global Registry of Acute Coronary Events (GRACE) data from 2007 
showed that 38% of patients had STEMI, 29% had NSTEMI and 29% had 
Unstable Angina (UA). Among women, UA and NSTEMI were more common 
than STEMI. However, among men, STEMI was more common. NSTEMI was 
more common in older men than in younger men. 
A clinical classification was developed further dividing MI into 5 types
4
 
CLINICAL CLASSIFICATION OF DIFFERENT TYPES OF MI : 
 
   Type 1 
   
     Spontaneous MI related to ischemia from  
        coronary plaque rupture or dissection 
 
 
   Type 2 
     
    MI due to ischemia resulting from increased  
     oxygen demand or decreased blood supply 
 
 
   Type 3 
 
    
  Sudden cardiac death with symptoms of ischemia,   
  new ST elevation or LBBB or coronary thrombus 
 
 
   Type 4a 
 
   
      MI associated with PCI 
 
   Type 4b 
 
   
      MI associated with stent thrombosis 
 
  Type 5 
         
   
      MI associated with CABG 
 
Included in this classification was sudden cardiac death when there is 
evidence of myocardial ischemia (new ST elevation, left bundle branch block or 
coronary thrombus), biomarker elevation > 3 times the upper reference limit for 
post percutaneous coronary intervention (PCI) patients or > 5 times the upper 
reference limit for post coronary artery bypass grafting (post CABG) patients. 
Documented stent thrombosis was also added in this new classification. 
ACS            Prevalence in Asians 
4
  
Unstable angina               51.4%  
NSTEMI            20.9% 
STEMI            16.5%  
STEMI 
STEMI is a clinical syndrome defined by characteristic symptoms of 
myocardial ischemia in association with persistent electrocardiographic (ECG) ST 
elevation and subsequent release of biomarkers of myocardial necrosis.  
An occlusive thrombus in the absence of significant collateral vessels results 
in acute ST elevation MI.  
ECG DIAGNOSIS OF STEMI 
 European Society of Cardiology/ACCF/AHA/World Heart Federation Task 
Force for the Universal Definition of Myocardial Infarction as  
 New ST elevation at the J point in at least 2 contiguous leads of   
 ≥ 2 mm (0.2 mV) in men or  
 ≥ 1.5 mm (0.15 mV) in women in leads V2–V3 and/or 
 ≥ 1 mm (0.1 mV) in other contiguous chest leads or the limb leads  
 New or presumably new LBBB has been considered a STEMI equivalent. 
 In the presence of pre-existing LBBB, MI is diagnosed using the Sgarbossa 
criteria. Total score of 3 or more has a 90% specificity and 88% positive predictive 
value. 
Sgarbossa criteria :
4
 
 ST segment elevation    ≥ 1mm concordant with QRS – 5 points 
 ST segment depression  ≥ 1mm in lead V1, V2 or V3 – 3 points 
 ST segment elevation    ≥ 5mm discordant with QRS – 2 points 
NSTEMI 
             With both stable angina and UA, ischemia is fully reversible, with no 
evidence of myocardial necrosis. UA may or may not be associated with signs of 
ischemic changes on electrocardiography (ECG), such as ST segment depression 
or new T wave inversion. UA is closely related to NSTEMI, and the two entities 
are often indistinguishable from each other, especially during the initial evaluation 
of a patient. However, NSTEMI is associated with myocardial necrosis and 
resultant release of cardiac biomarkers. 
VITAMIN D DEFICIENCY AND ITS ASSOCIATION WITH     
CARDIOVASCULAR DISEASES  
 
        It has been estimated that 1 billion people worldwide suffer from Vitamin D 
deficiency or insufficiency.
60
 It is only in the last 15 years that emphasis has 
emerged regarding the extra skeletal manifestations of Vitamin D deficiency. An 
epidemiological link between low 25(OH) Vitamin D levels and an increased 
cardiovascular risk has been now recognized in many observational studies. In a 
large randomized trial by Wang et al 
91
, the relative risk of MI for those with 
sufficient Vitamin D levels was 0.43 and individuals with Vitamin D deficiency 
showed a hazard ratio of 1.62 for incident cardiovascular events. 
    
                
Hazard ratio for Cardiovascular Diseases based on Vitamin D levels 
 
                       
They also demonstrated that there was increased cardiovascular risk in 
patients with hypertension (A) than in patients without (B) hypertension if their 
serum Vitamin D was < 15 ng/ml, in the Kaplan meier curves shown above.
91
                                                                      
Vitamin D mainly acts through its role in maintaining calcium homeostasis 
and gene transcription to prevent cardiovascular diseases and its risk factors. The 
high prevalence of cardiovascular disease in renal failure has also been linked with 
low Vitamin D. Up to 40% increase in cardiovascular mortality in winter season 
has also been linked to poor Vitamin D status.
52 
 
MECHANISMS FOR PROTECTIVE ACTION OF VITAMIN D IN  
CARDIOVASCULAR DISEASES            
PROTECTIVE ACTION ON THE ENDOTHELIUM 
Vitamin D exerts its protective effects on the endothelium directly by 
regulating calcium ion entry or indirectly by protecting against oxidant stress. 
Vitamin D deficiency leads to endothelial dysfunction by causing a 
proinflammatory and prothrombotic environment. This promotes atheroma 
formation and progression. Vitamin D deficiency is associated with high levels of 
Matrix Metalloproteinase 9 which causes vascular remodeling and increases 
arterial tone.
88
 
INHIBITION OF RENIN 
Yan Chun Li et al 
90
demonstrated that Vitamin D Receptor (VDR)  knockout 
mice developed hypertension, cardiac muscle hypertrophy and increased activation 
of the renin angiotensin aldosterone axis. They also demonstrated suppression of 
renin mRNA expression in the wild type mice that were given supplements of 
Vitamin D3. 
Inhibition of renin gene expression occurs by sequestration of cAMP 
response element binding thereby inhibiting transcription of renin mRNA. 
REGULATION OF PARATHORMONE                                       
Vitamin D inhibits vascular smooth muscle proliferation and calcification by 
regulating Parathormone (PTH) levels. Parathormone promotes calcium deposition 
in vascular smooth muscle. Optimum Vitamin D levels inhibit PTH which, in high 
levels, is responsible for pathogenesis of many factors that increase the risk for 
heart disease and its adverse effects on the blood vessels.
28
 
Vitamin D improves calcium uptake, inhibits platelet aggregation, increases 
nitric oxide synthase, inhibits thrombotic activity and also regulates the vasomotor 
reactivity to neural input. 
IMMUNOMODULATORY EFFECTS – ANTI INFLAMMATORY ACTION 
It reduces the proliferation of lymphocytes and the production of cytokines 
that promote atherogenesis. Its deficiency is associated with higher  
C-reactive protein and IL-6 levels and lower IL-10 levels. 
It inhibits prostaglandin and cyclo-oxygenase 2 activity, reduces matrix 
metalloproteinase 9 and many other pro-inflammatory cytokines which result in 
suppressed inflammation.
88
 
PLAQUE STABILITY 
Vitamin D inhibits the production of several pro-inflammatory cytokines 
while stimulating the effects of TH2 lymphocytes causing a reduction in matrix 
metalloproteinase. This reduces plaque production and instability.  
Laboratory studies of Vitamin D deficiency in mice have demonstrated 
increased thrombogenicity.  
VITAMIN D AND EFFECT ON CARDIAC HYPERTROPHY 
The Vitamin D receptor is present in virtually all tissues, including 
cardiomyocytes and endothelial cells. Vitamin D reduces the risk of cardiac 
hypertrophy through direct and indirect actions. Vitamin D directly acts to  reduce 
cell size and inhibit the maturation of these myocytes and acts indirectly through 
protein kinase C which is activated by norepinephrine, angiotensin II or PTH. 
Thus, by inhibiting PTH activity and by suppression of renin gene, Vitamin D can 
prevent cardiac muscle hypertrophy. 
Hypovitaminosis D and cardiovascular complications 
 
 
EFFECT ON CARDIAC CONTRACTILITY 
Low Vitamin D levels result in reduced myosin isozyme in the ventricular 
muscle cells and hence reduced cardiac contractility. Inhibition of PTH induced 
calcium resorption from bone reduces the risk of cardiac valvular and vascular 
calcification. 
 
VITAMIN D AND THE RISK OF ARRHYTHMIAS 
Vitamin D deficiency can lead to arrhythmias due to disruption of calcium 
homeostasis because intracellular calcium plays an important role in regulating the 
activity of sodium channels to control the heart rate. 
VITAMIN D AND ATHEROSCLEROSIS  
PTH increases the risk of atherosclerosis by promoting the formation of 
intra-arterial plaque. Hence suppression of PTH activity reduces calcification and 
stenosis in the blood vessels.
28
 
Vitamin D maintains normal vascular tone by promoting nitric oxide 
synthase production which suppresses platelet aggregation and thrombogenic 
activity. Many bone proteins governed by Vitamin D like matrix Gla protein and 
osteoprotegerin are present in the vessel wall and responsible for calcification of 
vessels in case of Vitamin D deficiency.  
Vitamin D, through its anti inflammatory actions, affects dendritic cells and 
macrophages in such a manner that it reduces foamy macrophages and suppresses 
cholesterol uptake. 
Moreover, the activity of Vitamin D is found to be enhanced by certain 
cardiac drugs such as beta blockers, thiazide diuretics, aspirin, etc. which suggests 
it may allow a reduction in drug dosages and hence its adverse effects. Statins 
increase Vitamin D levels by 70% after one year of treatment. 
REGULATION OF OTHER CARDIOVASCULAR RISK FACTORS 
Vitamin D, by inhibiting the renin angiotensin axis plays a vital role in 
controlling hypertension and preventing its adverse effects on the heart. 
Vitamin D improves Insulin Sensitivity thereby reducing the incidence of 
diabetes mellitus and the associated risk of accelerated atherosclerosis.  
VITAMIN D DEFICIENCY AND TYPE 2 DIABETES MELLITUS 
The current prevalence of Type 2 DM is high in urban and rural India
50
 and 
it is estimated that by the year 2030 India would harbor the maximum number of 
diabetics in the world.
26
  
Several studies by Pittas et al have showed significantly increased risk of 
type 2 diabetes when Vitamin D levels fall less than 30 ng/ml
25. It has also been 
noticed that glycemic status worsens during winter and this is associated with 
reduced 25(OH)D.
27 
The pancreas has VDR and 1α hydroxylase activity and hence it can convert 
25(OH)D to 1,25(OH)2D to act in a paracrine or autocrine manner. Vitamin D 
deficiency can result in insulin resistance or reduced insulin secretion.  
Mechanisms of Vitamin D in Type 2 DM : 
i. improves β cell function directly or by increasing the intracellular ionized 
calcium which enhances insulin release 
ii. increases insulin sensitivity by increasing the expression of insulin receptors 
and calcium dependent pathways in target cells that enhance glucose 
utilization  
iii. inhibits β cell apoptosis 25 
VITAMIN D DEFICIENCY AND HYPERTENSION  
Pfeifer et al demonstrated a 9% fall in systolic BP after supplementing 
vitamin D (800 IU).
28
 In another study, patients exposed to UVB radiation thrice a 
week for 3 months showed that 25(OH)D raised by 180% and both systolic and 
diastolic BP decreased by 6 mm Hg. As opposed to this, a large prospective study 
by Forman et al found no correlation between vitamin D supplementation and 
hypertension.
29 
Several mechanisms are implicated: 
 Suppression of the Renin Angiotensin Aldosterone axis 
 Direct effect on endothelial cells 
 Regulation of Calcium metabolism30    
 Nor Epinephrine and Angiotensin II play a vital role in the pathophysiology 
of hypertension. Impaired regulation can result in arrhythmias and 
myocardial infarction. 
 Patients with chronic kidney disease treated with Vitamin D show 20% fall 
in death rates and have also demonstrated the antiproteinuric effect of Vitamin D.
49 
Shown below is an illustration that briefly summarizes the various 
mechanisms by which Vitamin D deficiency can lead to adverse cardiovascular 
events. 
 
 
VITAMIN D 
SYNTHESIS AND METABOLISM OF VITAMIN D 
Vitamin D is a secosteroid. It refers to a group of fat soluble vitamins. The 
main  precursors are Vitamin D2 (ergocalciferol) and Vitamin D3 
(cholecalciferol).
20
 
7-dehydrocholesterol in the skin is converted to previtamin D3 on exposure 
to Ultraviolet B (UVB) rays of wavelength 290-320 nm. It is immediately 
converted to Vitamin D. About 40 to 50% of circulating 25(OH)D is derived from 
skin. Vitamin D2 is formed in plants and obtained from diet.  
Vitamin D2 and D3 are converted to 25-hydroxyvitamin D (calcidiol) in the 
liver by 25 hydroxylase activity. Biologically active 1,25-dihydroxyvitamin D 
(calcitriol) is formed by 1α hydroxylation in the kidneys. 
 
MECHANISM OF ACTION 
Circulating 25(OH)D is converted to the active hormone 1,25(OH)2D. 
Calcitriol is transported in the blood by Vitamin D Binding Protein (VDBP) and is 
carried to many target organs. This acts through the Vitamin D receptor (VDR) 
which belongs to the nuclear receptor superfamily. After activation, this receptor 
dimerizes with the Retinoid X Receptor (RXR) and binds to Vitamin D responsive 
elements that regulate the transcription of various genes in the target cells. 
More than 500 genes have been identified and around 37 different cell types 
are found to express VDR.
11
 The Vitamin D receptor is present in almost all cells 
in the body and the 1α hydroxylase enzyme is found in many tissues. Around 10% 
of the human genome is regulated by Vitamin D. This ubiquitous nature of 
Vitamin D receptor is responsible for its pleiotropic actions. 
                     
SOURCES OF VITAMIN D 
SUNLIGHT 
The main natural source is ultraviolet B rays in sunlight. Twenty to thirty 
minutes of sunlight exposure between 10am and 3pm two or three times a week is 
considered sufficient. UVB exposure does not cause Vitamin D intoxication 
because excess UVB rays convert Vitamin D3 into inactive metabolites, 
tachysterol and lumisterol. UVB (0.5 MED) provides 3000 IU of Vitamin D3.  
Shade and severe pollution reduces UVB rays by 60%.
2
 These rays don‟t 
penetrate glass, so indoor exposure of sunlight is of no use.
3 
Sunlight provides 
more quantity and more active Vitamin D than any other source.
 
FOOD
12
 
Cod liver oil and oily fish are very good sources of Vitamin D3. Vegetables 
are generally a poor source and hence food fortification programmes play an 
important role. 
Salmon fish  (100gm)      600 -1000 IU of Vitamin D3 
Mackerel fish (100gm)    250 IU of Vitamin D3 
Tuna fish (100gm)           230 IU of Vitamin D3 
Cod liver oil (1 tsp)         400 -1000 IU of Vitamin D3 
Egg yolk                         20 IU of Vitamin D3  
SUPPLEMENTS 
Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol) are available 
as supplements but Vitamin D3 is most effective. 
HYPOVITAMINOSIS D 
There are many guidelines and experts that define different cut off values to 
assess hypovitaminosis D. But recent consensus suggests to take Serum 25(OH)D 
> 30 ng/ml as the “cut off” value because this is the threshold at which 
parathormone secretion is induced and optimum calcium absorption occurs.⁷ 
25(OH) VITAMIN D – REFERENCE RANGES 21 
• < 15 ng/ml - Vitamin D Deficiency 
• 15.1-29.9 ng/ml - Vitamin D Insufficiency 
• > 30 ng/ml - Vitamin D Sufficiency 
• > 75 ng/ml - Vitamin D Intoxication 
Vitamin D Deficiency is further classified as: 
• <5 ng/ml - severe Hypovitaminosis D 
• 5-10 ng/ml - moderate Hypovitaminosis D 
• 10-15 ng/ml - mild Hypovitaminosis D                                   
PREVALENCE OF HYPOVITAMINOSIS D 
One billion people worldwide are estimated to be Vitamin D deficient.   
According to the World Health Organization, it is estimated that Vitamin D 
insufficiency is present in 50 to 80% of the population.
21
                 
It was only in the year 2000 that systematic studies of Vitamin D status were 
initiated in India and one such study showed that up to 90% of people in Delhi had 
low Vitamin D levels.
86
 Subsequent studies have shown widespread Vitamin D 
Deficiency (VDD) in Indians irrespective of age or sex in both rural and urban 
areas.
9 
GLOBAL BURDEN : An estimated loss of 3.3 billion DALYs from bone 
disease due to Vitamin D deficiency, and Vitamin D insufficiency leading to other 
diseases that constitute 9.4% of the global disease burden has been reported.
12
 
CAUSES FOR VITAMIN D DEFICIENCY 
REDUCED SKIN SYNTHESIS 
 Sunscreen use, skin pigmentation, aging and obesity reduce UVB related 
skin synthesis of Vitamin D. Season, latitude and time of day also determine 
skin production of Vitamin D. 
 Elderly persons have  reduced 7 dehydrocholesterol and spend less time 
outdoors. 
 Dark skinned individuals have more melanin which competes with 7 
dehydrocholesterol for absorption of UVB rays. 
 Sunscreens with a sun protection factor (SPF) of 8 or more block UV rays.  
INADEQUATE DIETARY INTAKE  
 Infants, children and elderly are especially susceptible.  
 Poor vitamin D content in human breast milk is another important factor.4  
REDUCED BIOAVAILABILITY 
 Malabsorption disorders5 
 Obesity –Vitamin D is sequestered in body fat 
 Drug interactions – Antiepileptics, Glucocorticoids, Rifampicin 
 Liver failure - Impaired synthesis of 25(OH)D 
 Renal failure – Impaired 1α hydroxylase activity 
INCREASED LOSS OF 25(OH)D 
 Nephrotic syndrome - urinary loss of 25(OH)D bound to Vitamin D binding 
protein  
REDUCED SYNTHESIS OF ACTIVE VITAMIN D 
 Chronic kidney disease  
 Hyperphosphatemia increases fibroblast growth factor (FGF-23) which 
reduces 1α hydroxylase activity⁶ 
INHERITED DISORDERS  
 Vitamin D dependent rickets 
 Vitamin D resistant rickets  
 Hypophosphatemic rickets - Autosomal dominant and X-linked 
ACQUIRED DISORDERS 
 Tumor induced osteomalacia - tumor secretion of FGF 23  
 Primary hyperparathyroidism 
 Granulomatous diseases like sarcoidosis, tuberculosis and some lymphomas 
 Hyperthyroidism - increase metabolism of 25(OH)D 
VITAMIN D DEFICIENCY – INDIAN SCENARIO
9
 
It was previously a general misbelief that Vitamin D deficiency was not 
prevalent in India because our country is situated near the equator and receives 
ample sunshine. But recent data has proved that Vitamin D deficiency is very 
common in India (approximately 50- 90%).
62
  
      Several factors contribute to Vitamin D deficiency in India :  
1. Diets low in calcium and Vitamin D especially in vegetarians. 
2. High fibre content, phosphates and phytates in diet. 
3. With urbanization, less time spent outdoors has led to inadequate sun 
exposure.  
4. Humid and sultry climate reduces outdoor exposure to sunlight 
5. Increased pollution hampers the ultraviolet rays. 
6. Customs like Burqa/Pardah in Muslims. 
7. Repeated and unspaced pregnancies can aggravate Vitamin D deficiency in 
the mother and the fetus. 
8. Darker skin pigmentation  
9. Lack of Vitamin D food fortification programmes 
10.  Liver, kidney, skin disorders, alcoholics, genetic factors, malabsorption 
disorders and inflammatory rheumatological conditions can lead to Vitamin 
D deficiency 
                               
VITAMIN D DEFICIENCY & CLINICAL DISEASE STATES 
SYMPTOMS OF VITAMIN D DEFICIENCY  
 Many people remain asymptomatic or present with multiple non specific 
complaints such as⁹ 
 Fatigue, general muscle pain and weakness, muscle cramps 
 Joint pain, weight gain, restless sleep 
 Poor concentration  
 Headache 
DISEASES ASSOCIATED WITH VITAMIN D DEFICIENCY 
 Rickets and Osteomalacia 
 Osteoporosis and Osteopenia 
 Malignancy 
 Cardiovascular diseases, Hypertension 
 Obesity, Metabolic Syndrome and Diabetes 
 Autoimmune diseases, Multiple sclerosis 
 Rheumatoid arthritis, Osteoarthritis 
 Parkinson‟s Disease, Alzheimer‟s Disease 
 Depression and Seasonal Affective Disorder 
 Chronic fatigue syndrome, Fibromyalgia 
VITAMIN D DEFICIENCY AND BONE HEALTH IN INDIANS 
Vitamin D plays a vital role in maintaining serum calcium and phosphorus. 
In the absence of Vitamin D, only 10 to 15% of dietary calcium and 60% of 
phosphorus is absorbed.
12-14
 Thus, Vitamin D is critical for skeletal mineralization.  
Vitamin D deficiency causes secondary hyperparathyroidism and increases 
bone resorption leading to osteopenia and osteoporosis. Raised parathormone 
induces phosphaturia and hypophosphataemia causing defective mineralization of 
the osteoid. 
Rickets and Osteomalacia are widely prevalent in India.
21
 The associated 
pseudofractures are due to low peak bone mass. There is also wide prevalence of 
biochemical osteomalacia and osteoporosis in our population detected on routine 
screening. The beneficial effects of 25(OH) D on skeletal health starts from fetal 
life and infancy and continues up to adulthood.
12 
Numerous observational studies by Hollick et al , Dawson Hughes et al and 
many others have linked low levels of 25(OH)D to fractures.
20
 But evidence is not 
consistent as some studies contradict these findings. Vitamin D deficiency has also 
been associated with osteoarthritis of the knee and hip joint.²⁴ 
MUSCLE WEAKNESS 
Skeletal muscle contains Vitamin D receptors and Vitamin D 
supplementation improves muscle metabolism. Many patients with nonspecific 
muscle weakness and muscle pains have inadequate Vitamin D levels.  
NEWBORNS AND VITAMIN D DEFICIENCY 
Vitamin D induces more than 3000 genes that affect fetal development⁴¹ and 
thus plays a critical role in brain development and function.
42
 It is essential to 
maintain Vitamin D sufficiency in utero and during early life to ensure normal 
receptor transcriptional activity in the brain. 
Up to 84% of pregnant women in India have Vitamin D Deficiency which 
correlated well with reduced serum 25(OH) D in their newborns. Their off springs 
had reduced intrauterine development and postnatal skeletal growth.
43
 Human 
breast milk contains very little Vitamin D and exclusively breast fed infants are 
have increased risk of rickets. Vitamin D deficiency compromises length from 
birth itself and continues into childhood, finally compromising adult height. 
VITAMIN D DEFICIENCY AND AUTOIMMUNITY  
Autoimmune diseases like type 1 diabetes mellitus, inflammatory bowel 
disease, rheumatoid arthritis
32
 and multiple sclerosis are linked to Vitamin D 
deficiency as VDR are present on monocytes, macrophages, dendritic cells, WBCs, 
CD4+ and CD8+ T cells and thus affect immune response in our body. Vitamin D 
inhibits cytokine production and T cell proliferation. 
54
 
Epidemiological data show correlation between Vitamin D deficiency and 
seasonal variation in the onset of these autoimmune disorders.
55
 Vitamin D has 
been found effective in improving and preventing Multiple Sclerosis by increasing 
TGF β levels.31 
VITAMIN D DEFICIENCY AND TUBERCULOSIS:  
Cod liver oil and high doses of Vitamin D was initially used to treat 
tuberculosis in the 1770s and continued till the 19th century, before the advent of 
ATT, on the basis that Vitamin D would cause calcification of tuberculosis 
lesions.
33
Low serum Vitamin D is an independent risk factor for TB in South 
Asians.
34
Vitamin D increases cathelicidin in the macrophages which promotes 
killing of the intracellular mycobacteria  
VITAMIN D DEFICIENCY AND MALIGNANCY 
People living at higher latitudes are found to be at high risk for varieties of 
malignancies such as Hodgkin‟s lymphoma, colon, pancreatic, prostate, ovarian, 
breast and other cancers due to low Vitamin D levels. 
 
Vitamin D regulates the cell cycle and induces apoptosis and cell 
differentiation. It inhibits tumor growth, angiogenesis and metastasis. Some studies 
have demonstrated 30-50% reduction in the risk of malignancy after vitamin D 
supplementation.
40 
 
DIAGNOSIS OF VITAMN D DEFICIENCY 
25(OH)D is the main circulating form of Vitamin D and it is the most 
sensitive marker to assess Vitamin D status in the general population. This is 
because 25(OH)D  can be easily measured and it has a long half life of around 2 to 
3 weeks. Moreover, serum 25(OH)D levels correlate well with clinical disease 
states.
65
  
Serum calcium is usually found to be normal in people with Vitamin D 
deficiency. 1,25-dihydroxyVitamin D is a poor indicator of deficiency states 
because it has a short half life of 15 hours and is very easily affected by 
parathormone, calcium and phosphorous.
60 
Also the levels of 1,25(OH)2D fall only 
when Vitamin D deficiency is severe. It is misleading because its values may be 
normal or even raised. 
METHODS TO ASSESS 25(OH)D LEVELS 
 Ligand-Binding Assays  
- Radioimmunoassay 
- Competitive protein-binding assays 
- Chemiluminescence assay 
 High-performance liquid chromatography (HPLC) 
 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
- Accurate and precise and considered the “Gold standard” method.  
 
TARGET LEVELS OF 25(OH) VITAMIN D 
      
            Serum 25(OH)D Concentrations and Health  
    nmol/L          ng/mL               Health status 
     <37.5            <15                 Deficiency 
   37.5–75          15-30               Insufficiency 
       ≥75            ≥30                Sufficiency 
    >187.5           >75                  Toxicity                                   
1 nmol/L = 0.4 ng/mL  
 
TREATMENT OF VITAMIN D DEFICIENCY 
Dosing 
67
 
 As per the Institute of Medicine (IOM), Vitamin D supplementation is based 
on the level of deficiency and treatment should be individualized. 
 25(OH)D  < 20 ng/mL (50 nmol/L)       50,000 IU of Vitamin D2 or D3 
orally once a week for 6 to 8 weeks, followed by 800 to 1000 IU of Vitamin 
D3 daily. 
 25(OH)D  20 to 30 ng/mL (50 to 75 nmol/L)     800 to 1000 IU of Vitamin 
D3 daily for 3 months. 
 In infants and children whose 25(OH)D is <20 ng/mL (50 nmol/L)   1000 
to 5000 IU of Vitamin D2 daily for 2 – 3 months. 
 1000 mg of calcium daily for premenopausal women and men and 1200 mg 
daily for postmenopausal women should also be supplemented along with 
Vitamin D. 
 Blood levels of 25(OH)D must be monitored three months after beginning 
treatment and dose adjustments may be made subsequently. 
To maintain sufficient Vitamin D levels, 50,000 IU of Vitamin D2 two times 
a month or 1000-2000 IU of Vitamin D3 is given daily.
60
  
PREVENTION OF VITAMIN D DEFICIENCY 
People with Vitamin D deficiency have no obvious symptoms until it is so 
severe that they develop osteomalacia. These patients are usually misdiagnosed as 
fibromyalgia as there is a general lack of awareness regarding the dangers of 
Vitamin D deficiency and the health benefits associated with Vitamin D.  
Although, there is adequate sunshine in India, high temperatures during 
daytime and humid climate in many areas are hindrance for adequate sun exposure. 
Hence, food fortification programs and public health campaigns that emphasize the 
consequences of Vitamin D deficiency on health are required. 
Vitamin D deficiency and its complications can be prevented by adequate 
Vitamin D supplementation, sun exposure, fortification of foods and  public 
awareness campaigns. Vitamin D supplementation must be advised to the general 
public and the dosing depends on the skin color, degree of sun exposure, diet and 
underlying medical conditions. 
 
Recommended Dietary Allowances (RDAs) for Vitamin D 
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Age Male Female Pregnancy Lactation 
0–12 months 400 IU(10mcg) 400 IU (10mcg)   
1–13 years 600IU(15mcg) 600 IU(15mcg)   
14–18 years 600 IU(15mcg) 600 IU(15mcg) 600 IU(15mcg) 600 IU(15mcg) 
19–50 years 600IU (15mcg) 600 IU(15 mcg) 600IU (15mcg) 600 IU(15mcg) 
51–70 years 600IU (15mcg) 600 IU(15 mcg)   
>70 years 800IU(20mcg) 800 IU(20 mcg)   
(40 IU = 1 mcg) 
 
It is currently recommended to take 1-1.5 g of calcium and 2000 IU of 
Vitamin D daily in order to prevent Vitamin D deficiency and its consequences in 
the Indian population. 
VITAMIN D - DRUG INTERACTIONS 
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Increase metabolism of Vitamin D and decrease serum levels:  
Phenytoin, Fosphenytoin, Phenobarbital, Carbamazepine, Rifampin, 
Theophylline, Cimetidine, Non-nucleoside reverse transcriptase inhibitors  
Decrease the intestinal absorption of Vitamin D:  
Cholestyramine, Colestipol, Orlistat, Mineral oil and fat substitutes 
Others:  
Ketoconazole inhibits 1α hydroxylase enzyme and reduces serum Vitamin D 
levels. Hypercalcemia caused by Vitamin D toxicity can precipitate cardiac 
arrhythmias in patients on digoxin. Corticosteroids reduce calcium absorption and 
impair Vitamin D metabolism. Statins and thiazide diuretics increase serum 
Vitamin D levels. 
HYPERVITAMINOSIS D 
         Vitamin D intoxication is extremely rare. It can result from over treating 
Vitamin D deficiency without monitoring serum levels or from poisoning. 
         Doses more than 10,000 IU /day can cause acute hypercalcemia and 
hyperphosphatemia where serum levels of 25(OH)D are >150 ng/ml (375 
nmol/L).
71 
 
          Caution should be exercised while treating patients of chronic 
granulomatous disorders like sarcoidosis and tuberculosis because macrophages 
produce 1,25(OH)D can precipitate hypercalcemia and  hyperphosphatemia.
70 
Primary hyperparathyroidism and lymphoma also increase the risk of 
hypercalcemia in response to Vitamin D. 
 
TOLERABLE UPPER INTAKE LEVEL FOR VITAMIN D 
70 
As per the Institute of Medicine (IOM), 
Infants:    0 - 6  months   – 1000 IU/day 
                 6 - 12 months  – 1500 IU/ day 
Children:  1-3 years    –   2500 IU/day 
                  4 - 8 years  – 3000IU/day 
Adults:     > 9 years    – 4000 IU/day 
As per the European Food and Safety Authority (EFSA), 
0 - 10 years – 1000 IU/day 
> 11 years   - 2000 IU/day 
CLINICAL FEATURES OF HYPERVITAMINOSIS D 
 Headache,  Lethargy, Dehydration 
 Nausea, Vomiting, Abdominal Pain  
 Constipation, loss of appetite  
 Failure to Thrive (In Children) 
 Polyuria, Polydipsia 
 Renal stones  
 Increased risk of pancreatic cancer, vascular calcification and death has been 
associated with serum levels of 25(OH)D > 60 ng/ml (150 nmol/L ) 
 Increased 1α hydroxylase activity led to premature aging in mice72. 
MANAGEMENT OF HYPERVITAMINOSIS D 
Rapid treatment with intravenous fluids, steroids and calcium restricted diet. 
Some may require bisphophonates to control hypercalcemia.
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MATERIALS AND METHODS 
 
SETTING :  Government Royapettah Hospital, Chennai 
 
 
COLLABORATIVE DEPARTMENT :  Department of Cardiology, GRH 
 
 
STUDY DESIGN :  Observational Case Control Study 
 
 
PERIOD OF STUDY :  April 2012 to September 2012 
 
 
SAMPLE SIZE :  100 cases ( 50 cases ; 50 controls) 
 
 
INCLUSION CRITERIA: 
 
1. Patients with acute ST Elevation Myocardial Infarction admitted in the 
Intensive Coronary Care Unit at GRH were selected as cases 
2. Patients without Diabetes / Hypertension / Coronary Artery Disease who 
attended the medical OPD were selected as controls 
3. Patient‟s age > 18 years 
 
EXCLUSION CRITERIA: 
 
1. Age < 18yrs 
 
2. Diabetes 
 
3. Hypertension 
 
4. Prior History of Cardiovascular disease 
 
5. Prior History of Cerebrovascular or Peripheral Vascular disease 
 
6. Renal disease  
 
7. Hepatic disease 
 
8. Prior history of vitamin D supplementation 
 
9. Patients on drugs that affect vitamin D metabolism  
 
(Anti Epileptics, Steroids, Rifampin) 
 
     10. History of Tuberculosis 
 
     11. Pregnancy and Lactation 
 
 
Cases and Controls were selected after considering the above inclusion and 
exclusion criteria 
 
ETHICAL CLEARANCE:  Obtained 
 
 
INFORMED CONSENT: 
  
Both the cases and controls study groups were informed about the nature of 
the study. Members who were willing to participate in this study were included 
after getting their written informed consent. 
 
METHODOLOGY: 
 
 Patients admitted with acute ST Elevation Myocardial Infarction in the 
Intensive Coronary Care Unit of Government Royapettah Hospital were chosen as 
cases. A total of 50 cases who satisfied the inclusion and exclusion criteria above 
were included in the study over a period of 6 months. 50 age and sex matched 
subjects were kept as controls.  
 A data collection form was prepared to note the Name, Age, Sex, 
Occupation, Address, Complaints, Past Medical History, Smoking, Alcoholism, 
Drug Intake and other relevant history. General Examination with examination of 
the Vital Signs, Cardiac,Respiratory, Abdomen and Central Nervous System was 
done. Each patient‟s clinical profile was noted. The ECG and ECHO reports of the 
patients were recorded. 
LABORATORY INVESTIGATIONS: 
 
Blood samples were drawn at the time of admission to measure the serum 
levels of 25(OH) Vitamin D, Random blood sugar and lipid profile. Renal function 
and hepatic function was assessed by measuring the urea, creatinine and total 
protein, serum bilirubin, serum albumin levels respectively. 
Serum levels of 25(OH) Vitamin D were measured using Chemi    
Luminescence ImmunoAssay technique. 
STATISTICAL ANALYSIS: 
 
Data was entered in Microsoft Excel spreadsheet and analyzed. Data 
analysis was done with the use of standard SPSS (Statistics Products Services 
Solutions) 16.0 software package. Descriptive statistics were used to calculate the 
frequency, mean and standard deviation.  Student „t‟ values was applied for 
significance. Significance was considered if the „p‟ value was below 0.05.  
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DEFINITIONS USED IN THE STUDY 
     
I. ACUTE ST ELEVATION MYOCARDIAL INFARCTION :  
 New ST elevation 4at the J point in at least 2 contiguous leads of 
   
 ≥ 2 mm in men or  
 
 ≥ 1.5 mm in women in leads V2–V3 and/or 
 
 ≥ 1 mm in other contiguous chest leads or limb leads 
 
 New onset LBBB  
 
II. SERUM 25(OH)D CONCENTRATIONS AND HEALTH 
STATUS :
21
 
 Vitamin D sufficiency      > 30 ng/ml 
 Vitamin D insufficiency      15.1 – 29.9 ng/ml 
 Vitamin D deficiency        < 15 ng/ml 
        Vitamin D deficiency is further classified as 
 <5 ng/ml - severe Hypovitaminosis D 
 5-10 ng/ml - moderate Hypovitaminosis D 
 10-15 ng/ml - mild Hypovitaminosis D 
III. BODY MASS INDEX : 
 
It is estimated by using the formula:  BMI = Weight (kg)/ Height²(m) 
 
  
A BMI of 
 < 18.5  underweight 
 18.5 - 24.9 normal 
 25.0 - 29.9  overweight 
 30  obese  
 
Obesity: 
 Class I     (BMI  30 to 39.9) 
 Class II    (BMI  40 to 49.9) 
 Class III  (BMI  >50) 
 
 
CLINICAL CLASSIFICATION OF OBESITY
81
  
Mortality and coronary heart disease risk 
                                                                                                 
 
Class of                     Body mass index                     Class 
Obesity                             (kg/m2) 
 
   0                                 20–25                                 Not obese 
   1                                 25–30                                  Mild risk 
   2                                 30–35                              Moderate risk 
   3                                 35–40                                  High risk 
   4                                  > 40                                Very high risk 
 
IV. NORMAL VALUES: 
 Serum albumin – 3.5 – 5.0 mg/dl 
 Serum calcium – 8.7 – 10.2 mg/dl 
 Serum triglycerides – 30 – 200 mg/dl 
 Serum cholesterol –  < 200 mg/dl  normal 
                                    200 – 239 mg/dl  borderline high 
                               240 mg/dl  high 
  
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS 
 
STUDY POPULATION CHARACTERISTICS 
A total of 100 subjects were included in this study out of which 50 were 
cases ( Acute Myocardial Infarction ) and 50 were controls. Both men and women 
between age of 25 to 80 years were included in the study. 
TABLE 1 : 
GROUP 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 Case 50 50.0 50.0 50.0 
Control 50 50.0 50.0 100.0 
Total 100 100.0 100.0  
 
FIGURE 1 : 
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TABLE 2 : GENDER WISE DISTRIBUTION OF PATIENTS 
 
   Sex 
Total    Male Female 
 
 
GROUP 
 
 
 
Case 
Count 45 5 50 
% within GROUP 90.0% 10.0% 100.0% 
  
Control 
Count 44 6 50 
% within GROUP 88.0% 12.0% 100.0% 
 
Total 
Count 89 11 100 
% within GROUP 89.0% 11.0% 100.0% 
p value - 1.000 (not significant) 
FIGURE 2 : GENDER WISE DISTRIBUTION OF PATIENTS 
 
 
Among the 50 cases studied, there were 45 (90%) males and 5 (10%) 
females.  Among the 50 controls, there were 44 (88%) males and 6 (12%) females. 
The sex composition of the case and control group did not differ significantly. 
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TABLE 3 : AGE WISE DISTRIBUTION OF PATIENTS 
   AGE 
Total    20-39yrs 40-59yrs >60yrs 
 
 
GROUP 
 
Case 
Count 7 27 16 50 
% within GROUP 14.0% 54.0% 32.0% 100.0% 
 
Control 
Count 5 32 13 50 
% within GROUP 10.0% 64.0% 26.0% 100.0% 
 
Total 
Count 12 59 29 100 
% within GROUP 12.0% 59.0% 29.0% 100.0% 
      p value – 0.586 (not significant) 
FIGURE 3 : AGE WISE DISTRIBUTION OF PATIENTS   
             
The mean age in the case and control groups were 51.72 ± 12.99 and 51.8 ± 
10.63 years respectively. The study population was stratified into 3 groups 
according to their age. There was no significant difference in the age distribution 
between the cases and controls in each of the three age groups. 
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TABLE 4 : CASES AND CONTROLS WITH RESPECT TO BMI  
 
   BODY MASS INDEX (kg/m²) 
Total    Normal Over weight Obese 
 
 
GROUP 
 
Case 
 Count 19 17 14 50 
% within GROUP 38.0% 34.0% 28.0% 100.0% 
 
Control 
 Count 31 16 3 50 
% within GROUP 62.0% 32.0% 6.0% 100.0% 
 
Total 
 Count 50 33 17 100 
% within GROUP 50.0% 33.0% 17.0% 100.0% 
        p value – 0.007 (significant) 
FIGURE 4 : CASES AND CONTROLS WITH RESPECT TO BMI 
 
The mean and standard deviation for the cases and controls were 27.14 ± 
3.88 and 24.5 ± 2.84 kg/m2 respectively. The Body Mass Index of the study group 
was significantly higher than that of the control group.  
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TABLE 5 : CASES AND CONTROLS WITH RESPECT TO SMOKING 
 
   Smoker 
Total    Yes No 
 
 
GROUP 
 
Case 
 Count 39 11 50 
% within GROUP 78.0% 22.0% 100.0% 
 
Control 
 Count 34 16 50 
% within GROUP 68.0% 32.0% 100.0% 
 
Total 
 Count 73 27 100 
% within GROUP 73.0% 27.0% 100.0% 
     p value – 0.368 (not significant) 
FIGURE 5 : CASES AND CONTROLS WITH RESPECT TO SMOKING 
 There 
was no significant difference between the number of smokers and non smokers 
among the cases and the controls. Hence, we could exclude smoking as a 
confounding factor for cardiovascular risk. 
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TABLE 6 : SERUM CHOLESTEROL IN STUDY GROUP 
 
   TOTAL CHOLESTEROL 
Total    <240mg% >240mg% 
 
 
GROUP 
 
Case 
 Count 46 4 50 
% within GROUP 92.0% 8.0% 100.0% 
 
Control 
 Count 50 0 50 
% within GROUP 100.0% 0% 100.0% 
 
Total 
 Count 96 4 100 
% within GROUP 96.0% 4.0% 100.0% 
     p value – 0.126 ( not significant) 
FIGURE 6 : SERUM CHOLESTEROL IN STUDY GROUP 
 
The mean serum cholesterol level in the cases was 209.02 ± 31.95 mg/dl and 
in the controls was 182.38 ± 20.33 mg/dl. The difference between the two groups 
was not statistically significant. 
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TABLE 7 : SERUM TRIGLCERIDES  IN STUDY GROUP 
   TRIGLYCERIDES(mg%) 
Total    <200 >200 
 
 
GROUP 
 
Case 
 Count 33 17 50 
% within GROUP 66.0% 34.0% 100.0% 
 
Contr
ol 
 Count 37 13 50 
% within GROUP 74.0% 26.0% 100.0% 
Total  Count 70 30 100 
% within GROUP 70.0% 30.0% 100.0% 
p value – 0.147 (not significant) 
FIGURE 7 : SERUM TRIGLCERIDES IN STUDY GROUP 
         
The mean serum triglyceride level in the cases was 170.94 ± 48.77 mg/dl 
and in the controls was 122.74 ± 23.57 mg/dl. The difference between the two 
groups was not statistically significant.  
TG > 200 mg%
CASES
CONTROLS
TG < 200 mg %
CASES
CONTROL
 TABLE 8 : SERUM CALCIUM IN STUDY GROUP 
 
   CALCIUM 
Total    9–11 mg% < 9 mg% 
 
 
GROUP 
 
Case 
 Count 45 5 50 
% within GROUP 90.0% 10.0% 100.0% 
 
Control 
 Count 45 5 50 
% within GROUP 90.0% 10.0% 100.0% 
 
Total 
 Count 90 10 100 
% within GROUP 90.0% 10.0% 100.0% 
  p value - 1.000 ( not significant) 
FIGURE 8 : SERUM CALCIUM IN STUDY GROUP 
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The mean serum calcium in the cases was 8.92 ±  0.74 mg/dl and in the 
controls was 9.09 ± 0.62 mg/dl. The difference between the cases and controls was 
not statistically significant 
TABLE 9 : VITAMIN D STATUS IN THE STUDY POPULATION 
   25(OH) VITAMIN D (ng/ml) 
Total    Deficiency Insufficiency Normal 
 
 
GROUP 
 
Case 
Count 32 18 0 50 
% within GROUP 64.0% 36.0% 0% 100.0% 
 
Control 
Count 13 25 12 50 
% within GROUP 26.0% 50.0% 24.0% 100.0% 
 
Total 
Count 45 43 12 100 
% within GROUP 45.0% 43.0% 12.0% 100.0% 
p value - 0.001 (significant) 
 FIGURE 9: VITAMIN D STATUS IN CASES AND CONTROL 
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Cases: 
None of the cases had normal vitamin D levels 
64% had Vitamin D deficiency  
36% had Vitamin D insufficiency 
 
Controls: 
Only 24% had normal vitamin D levels 
26% had Vitamin D deficiency 
50% had Vitamin D insufficiency  
The mean serum 25(OH) Vitamin D in the cases was 13.49 ± 5.35 ng/ml and 
the mean serum 25(OH) Vitamin D in the controls was 23.43± 12.52 ng/ml.   
The p value was 0.001 and this difference between the two groups was 
statistically significant showing significant Hypovitaminosis D among the cases. 
TABLE 9.1: SEVERITY OF VITAMIN D DEFICIENCY IN CASES AND CONTROLS 
 
   VITAMIN D DEFICIENCY < 15 ng/ml 
Total 
   
< 5 ng/ml 5 – 10 ng/ml 
10 – 15 
ng/ml 
 
 
GROUP 
 
Case 
Count 0 16 16 32 
% within GROUP 0% 36% 36% 72% 
 
Control 
Count 0 5 8 13 
% within GROUP 0% 11% 18% 29% 
 
Total 
Count 0 21 24 45 
% within GROUP 0% 47% 53% 100.0% 
 
FIGURE 9.1: SEVERITY OF VITAMIN D DEFICIENCY IN CASES AND CONTROLS 
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Cases: 
Severe Vitamin D deficiency  0% 
Moderate Vitamin D deficiency  36% 
Mild Vitamin D deficiency  36% 
 
Controls: 
Severe Vitamin D deficiency  0% 
Moderate Vitamin D deficiency  11% 
Mild Vitamin D deficiency  18% 
 
The patients who had vitamin D deficiency were further divided into three 
groups based on severity. None of them had severe deficiency.  
Moderate deficiency was present in 36% of cases but only in 11% of 
controls. 
Mild deficiency was present in 36% of cases and in 18% of controls  
TABLE 10:  GENDER WISE DISTRIBUTION OF VITAMIN D  
  Sex N Mean Std. Deviation P-value 
 
VIT. D 
(ng/ml) 
 
 
Male 
89 18.6980 10.99856 
0.536 
 
 
  Female 
11 16.5482 9.28151 
p value - 0.586 ( not significant) 
FIGURE 10 : GENDER WISE DISTRIBUTION OF VITAMIN D LEVELS 
IN CASES AND CONTROLS 
 
Among the cases, vitamin D deficiency was present in 28 males and 4 
females whereas vitamin D insufficiency was seen in 17 males and 1 female. 
In the controls group, sufficient vitamin D levels were seen in 9 men and 1 
woman. Vitamin D insufficiency was present in 23 men and 4 women. 12 men and 
1 woman had Vitamin D deficiency. 
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FIGURE 10.1 : VITAMIN D STATUS IN MALES AND FEMALES 
     
The total population included 89 males and 11 females. The mean Vitamin 
D level among males was 18.69 ng/ml and among females was 16.54 ng/ml. 
The p value was 0.586 and was not significant indicating that there was no 
significant difference between the gender distribution of vitamin D levels. 
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TABLE 11 : VITAMIN D STATUS IN EACH AGE GROUP 
 
 
 
AGE 
 
GROUP 
 
 
 
MEAN  25(OH) VITAMIN D                                                    
(ng/ml) 
 
 
CASES 
CONTROLS 
 
20-39yrs 
 
 
9.58 
 
26.52 
 
40-59yrs 
 
 
15.08 
 
24.15 
 
>60yrs 
 
 
13.54 
 
20.83 
 
FIGURE 11 : AGE WISE DISTRIBUTION OF VITAMIN D LEVELS 
             
The cases and controls were divided into 3 age groups and their vitamin D 
status was assessed. 
Among the cases, mean serum 25(OH)vitamin D in the age group 20-39yrs 
was 9.58ng/ml as compared to a mean value of 26.52ng/ml which showed a 
significant degree of vitamin D deficiency in young MI patients.  
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As for the patients in the age group 40-59yrs, the mean vitamin D levels in 
the cases was 15.08 and that of the controls was 24.15ng/ml.  
In the patients > 60yrs age, mean of 13.54ng/ml was found in the cases and 
20.83ng/ml in the controls.  
This denotes significant degree of Vitamin D deficiency in all the 3 age 
groups in the patients with Myocardial Infarction. The level of deficiency was 
more significant in the patients < 40yrs who presented with acute myocardial 
infarction. 
TABLE 12: CORRELATION OF VITAMIN D STATUS & BMI 
   BODY MASS INDEX 
Total    Normal Over weight Obese 
 
 
 
25(OH)          
Vitamin D 
(ng/ml) 
 
Deficiency 
 Count 14 18 13 45 
% within VIT.D_GP 31.1% 40.0% 28.9% 100.0% 
 
Insufficienc
y 
 Count 28 11 4 43 
% within VIT.D_GP 65.1% 25.6% 9.3% 100.0% 
 
Sufficiency 
 Count 8 4 0 12 
% within VIT.D_GP 66.7% 33.3% 0% 100.0% 
 
Total 
 Count 50 33 17 100 
% within VIT.D_GP 50.0% 33.0% 17.0% 100.0% 
p value - 0.007 (significant) 
FIGURE 12 : VITAMIN D STATUS AND BODY MASS INDEX
 
The Vitamin D levels were significantly lower in those with higher BMI in 
the study group.  
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TABLE 13: CORRELATION OF VITAMIN D & TOTAL CHOLESTEROL 
   TOTAL CHOLESTEROL 
Total    <240 >240 
 
 
 
25(OH)               
Vitamin D 
(ng/ml) 
 
Deficiency 
 Count 43 2 45 
% within VIT.D_GP 95.6% 4.4% 100.0% 
 
Insufficiency 
 Count 41 2 43 
% within VIT.D_GP 95.3% 4.7% 100.0% 
 
Sufficiency 
 Count 12 0 12 
% within VIT.D_GP 100.0% 0% 100.0% 
 
Total 
 Count 96 4 100 
% within VIT.D_GP 96.0% 4.0% 100.0% 
p value -  0.752 (not significant) 
FIGURE 13 : VITAMIN D & TOTAL CHOLESTEROL 
There 
was no significant correlation between Serum 25(OH) vitamin D and Total 
cholesterol levels in the cases and controls. 
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TABLE 14 : CORRELATION OF VITAMIN D & TGL 
   TRIGLCERIDE 
Total    <200 >200 
 
 
 
25(OH)          
Vitamin D 
(ng/ml) 
 
Deficiency 
 Count 32 13 45 
% within VIT.D_GP 71.1% 29.9% 100.0% 
 
Insufficiency 
 Count 31 12 43 
% within VIT.D_GP 72.1% 27.9% 100.0% 
 
Sufficiency 
 Count 8 4 12 
% within VIT.D_GP 66.6% 33.3% 100.0% 
 
Total 
 Count 71 29 100 
% within VIT.D_GP 71.0% 29.0% 100.0% 
p value -  0.400 (not significant) 
FIGURE 14 : VITAMIN D AND TRIGLYCERIDES 
 
There was no significant correlation between Serum 25(OH) vitamin D and 
triglyceride levels in the cases and controls. 
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TABLE 15 : CORRELATION OF VITAMIN D & SERUM CALCIUM 
   CALCIUM 
Total    9–11 mg% < 9 mg% 
 
 
 
25(OH)          
Vitamin D 
(ng/ml) 
Deficiency  Count 42 3 45 
% within VIT.D_GP 93.3% 6.7% 100.0% 
Insufficiency  Count 37 6 43 
% within VIT.D_GP 86.0% 14.0% 100.0% 
Normal  Count 11 1 12 
% within VIT.D_GP 91.7% 8.3% 100.0% 
 
Total 
 Count 90 10 100 
% within VIT.D_GP 90.0% 10.0% 100.0% 
p value -  0.512 (not significant) 
FIGURE 15 : CORRELATION OF VITAMIN D & SERUM CALCIUM 
 
There was no significant correlation between Serum 25(OH) vitamin D and 
Serum Calcium levels in the cases and controls. 
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TABLE 16 : CORRELATION OF VITAMIN D AND SERUM ALBUMIN 
   SERUM ALBUMIN 
Total    <3.5 g% >3.5g% 
 
 
 
25(OH) 
Vitamin D 
 
 
Deficiency 
 Count 6 39 45 
% within VIT.D_GP 13.3% 86.7% 100.0% 
 
Insufficiency 
 Count 4 39 43 
% within VIT.D_GP 9.3% 90.7% 100.0% 
 
Sufficiency 
 Count 2 10 12 
% within VIT.D_GP 16.7% 83.3% 100.0% 
 
Total 
 Count 12 88 100 
% within VIT.D_GP 12.0% 88.0% 100.0% 
p value -  0.734 (not significant) 
FIGURE 16 : VITAMIN D AND SERUM ALBUMIN 
 
 There was no significant correlation between Serum 25(OH) Vitamin D and 
Serum Albumin levels in the cases and controls. Hence Vitamin D levels were not 
biased by low serum albumin levels. 
0
5
10
15
20
25
30
35
40
45
VITAMIN D 
SUFFICIENCY
VITAMIN D 
INSUFFICIENCY
VITAMIN D 
DEFICIENCY
< 3.5g%
> 3.5g%
T-Test  
Statistical analysis was done by using the SPSS software. Student t test was used to 
derive statistical significance on comparing the following variables between the 
cases and controls. p value < 0.05 was considered significant. 
  
GROUP 
 
N 
 
 
Mean 
 
Std. Deviation 
 
P-value 
 
 
 
 
Age  
(years) 
  
Case 
 
50 51.72 12.998 
0.973 
  
Control 
 
50 51.80 10.633 
 
 
 
BMI 
(kg/m
2
) 
  
Case 
 
50 27.1370 3.87449 
0.000 
     
Control 
 
50 24.5016 2.83610 
 
 
 
 
T-Test 
  GROUP 
 
N 
 
Mean 
 
Std. Deviation 
 
P-value 
 
 
 
 
T.Chol. 
(mg/dl) 
  
Case 
 
50 209.02 31.952 
0.126 
     
Control 
 
50 182.38 20.329 
 
 
TGL 
(mg/dl) 
  
Case 
 
50 170.94 48.772 
0.147 
     
Control 50 122.74 23.576 
       
T - Test  
  GROUP 
 
N 
 
Mean 
 
Std. Deviation 
 
P-value 
 
 
 
 
VIT. D 
(ng/ml) 
  
Case 
 
50 13.4894 5.34646 
0.001 
     
Control 
 
50 23.4336 12.51863 
 
 
Calcium 
(mg/dl) 
  
Case 
 
50 8.9178 0.74067 
0.206 
     
Control 
 
50 9.0916 0.62002 
  
Among the study population of 50 cases and 50 controls, significant p value 
was observed between BMI > 25 kg/m
2
 and Hypovitaminosis D. 
  
 
 
DISCUSSION  
 
 
 
 
 
 
DISCUSSION 
In our study of 100 patients we included 50 cases of acute Myocardial 
Infarction and 50 age and sex matched controls. We had selected our cases on the 
basis that they had no previous history of Diabetes, Hypertension, Dyslipidemia or 
prior Cardiovascular disease because we wanted to study the association of low 
vitamin D levels as an independent risk factor for the occurrence of first 
cardiovascular event in a patient.  
We found a statistically significant correlation of Hypovitaminosis D in the 
patients with Acute Coronary Syndrome. All the patients who were admitted with 
acute MI had subnormal Vitamin D levels. 64% of the cases were deficient in 
Vitamin D (<15ng/ml) and 36% of the cases had insufficient levels (15-30ng/ml). 
In the control group, 26% had deficient levels and 50% had insufficient levels 
whereas only 24% of the control group had normal 25(OH) Vitamin D levels. The 
mean Vitamin D level among the cases was 13.5ng/ml and that among the controls 
was 24.3ng/ml and this was indicative of a statistically significant difference.  
In the CACTI study by Young et al,
87
 the association of Vitamin D 
deficiency with prevalent Coronary Artery Calcification was independent of 
known CAD risk factors, including confounders such as BMI and mediators such 
as lipids. This adds proof to the fact that Vitamin D is related to CAD through 
unique biologic mechanisms. 
It was observed in the Framingham heart study
88
 that those patients whose 
Vitamin D levels were <15ng/ml had a 60% greater incidence of cardiac events 
than those with higher levels. Though there are many meta analyses that have 
reported both positive and neutral correlations, some Indian studies have even 
reported that high levels of vitamin D may attribute to ischemic events. Shanker et 
al
84
 found that low vitamin D levels were associated with increased risk for CAD, 
in contrary to which, Rajasree et al reported a paradoxical increase in coronary 
heart disease with 25(OH)D levels >89 ng/mL compared to those with lower 
levels.
83
 Sanjeev kumar Syal et al
85
 observed a high prevalence of hypovitaminosis 
D in Indian patients with angiographically documented CAD. They demonstrated 
that patients with lower levels of Vitamin D had higher prevalence of severe 
(double- and triple-vessel CAD) and diffuse disease on coronary angiography, 
independent of established CV risk factors. In their study, endothelial dysfunction 
as assessed by brachial artery FMD was also more frequently observed in those 
with 25(OH)D levels.
85
 
On assessing the overall Vitamin D status in our study population of 100 
subjects, we found that only 12% had normal 25(OH)D levels. The remaining 88% 
had Hypovitaminosis D out of which 45% were deficient and 43% were 
insufficient in Vitamin D. The high rates of vitamin D deficiency in our study 
group is reflective of the high prevalence of Hypovitaminosis D in the Indian 
population as demonstrated in a study by Harinarayan et al which showed that 50-
90% of the people living in India are deficient in Vitamin D.⁶² 
The mean Vitamin D level in the control group was found to be 24.3ng/ml. 
This is similar to the NHANES 2005-2006 survey that showed a mean Vitamin D 
level of 24ng/ml among apparently healthy subjects.     
In our study, we also analyzed the association of Vitamin D with other 
parameters such as Age, Gender, Body Mass Index, Total cholesterol and 
Triglyceride levels, Serum albumin and Serum calcium.  
We did not find any significant association between the gender distribution 
of serum Vitamin D levels among the cases or controls. The mean serum Vitamin 
D level among the male subjects was 18.69ng/ml and among the female subjects 
was 16.54ng/ml indicating no specific correlation between gender and Vitamin D 
levels. 
The study participants were divided into three age groups in both the cases 
and controls. The mean Vitamin D level in the cases was lower than the controls in 
each age group. There was significant decrease in Vitamin D levels in the young 
CAD patients < 40yrs. Their mean Vitamin D level was only 9.58ng/ml when 
compared to the control group < 40yrs whose mean Vitamin D level was 
26.52ng/ml suggestive of a significant role of Hypovitaminosis D as an 
independent risk factor for Myocardial Infarction in the absence of other 
conventional risk factors. 
In our study, we found low Vitamin D levels in those with higher BMI. 
Body Mass Index > 25kg/m² was seen in approximately 70% of our patients with 
Vitamin D deficiency. This is in concurrence with many studies that link Vitamin 
D deficiency to high BMI, Obesity and the Metabolic Syndrome. 
We did not find any association between Dyslipidemia and 
Hypovitaminosis D. There was no significant association between the calcium 
levels in the cases and controls nor was there any significant association between 
low Vitamin D levels and hypocalcemia. Also, serum albumin levels did not 
correlate  with the Vitamin D status. 
High mortality rates associated with CAD in people living far away from the 
equator was studied by Fleck et al
73
 and Rostand et al.
76
 Grimes et al
74
 showed that 
mortality was inversely proportional to the amount of hours exposed to sunlight. 
He also proposed Vitamin D as a protective factor by regulating serum cholesterol 
levels and by inhibiting Chlamydia pneumonia. Douglas et al
75
 reported a strong 
seasonal variation with higher mortality rates in winter when Vitamin D levels are 
lowest. Many large prospective studies such as The Framingham Offspring Study, 
The Health Professionals Follow up Study, The Third National Health and 
Nutrition Examination Survey (NHANES III) have proved a positive association 
between low Vitamin D levels and the risk of adverse cardiac events.
77
 Hence, 
many studies suggest that poor Vitamin D status is associated with poor 
cardiovascular outcomes.  
But, the 2011 IOM report concluded that the evidence that vitamin D 
prevents cardiovascular disease was not consistent.
79
 Many reports argue that the 
25(OH)D acts as a acute phase reactant and its levels reduce significantly during 
disease processes, similar to other vitamins. Moreover, there isn‟t substantial 
evidence to state that a single hormone can be a harbinger of such severe and 
diverse disease processes.  
In spite of these controversies, there are multiple studies worldwide 
reporting positive correlation between low vitamin D levels and adverse cardiac 
events. Various studies have also claimed that Vitamin D supplementation has 
reduced the incidence of cardiovascular disease and its complications with a 
significant decrease in all cause mortality.
80 
Hence, to conclude, our study showed a positive correlation of low Serum 
25(OH) Vitamin D < 15ng/ml as a risk factor for Coronary Heart Disease. There 
was also a positive correlation of Hypovitaminosis D with high Body Mass Index  
> 25 kg/m
2
. There was no significance in the age and gender distribution of 
Vitamin D levels. Serum calcium did not correlate with the occurrence of CAD or 
with the severity of Vitamin D deficiency. 
SUMMARY 
Various epidemiologic data and observational studies show that serum 
vitamin D concentrations are lower in patients with coronary heart disease 
compared with healthy controls. However, Hypovitaminosis D is also associated 
with other cardiovascular risk factors like hypertension, diabetes, obesity, 
metabolic syndrome and dyslipidemia. 
 
The present study was proposed to assess the 25(OH)Vitamin D status in 
patients with acute Myocardial Infarction and to find its association with age, 
gender, BMI, dyslipidemia and serum calcium. Patients were selected carefully and 
evaluated after getting ethical clearance and informed consent. The study included 
50 cases of Acute Myocardial Infarction and 50 healthy age and sex matched 
controls. 
Our analysis revealed that serum 25(OH)Vitamin D levels were significantly lower 
in the cases of acute Myocardial Infarction when compared to the control 
population. Body Mass Index  >25 kg/m
2
 significantly correlated with 
hypovitaminosis D.  
 
Large randomized controlled trials are needed to firmly establish the 
relevance of vitamin D status to cardiovascular health. In the meanwhile, 
monitoring serum 25- hydroxyvitamin D levels and correction of vitamin D 
deficiency is indicated for optimization of general health”.  
LIMITATIONS OF THE STUDY 
 The main limitation in our study was the small number of subjects that were 
included.   
 Very few female patients were studied. Further studies need to be done with 
a larger study population including more women. 
 25(OH) Vitamin D estimation was not performed by the gold standard 
Liquid Chromatography Tandem Mass Spectrometry method. We used the 
Chemiluminescence assay for the quantitative determination of the 25(OH) 
Vitamin D levels in our patients. The concentration of vitamin D in each 
specimen may vary due to differences in methods and reagent specificity. 
 The Parathormone levels were not measured and hence its role as a 
confounding factor could not be analyzed.  
 The cause for hypovitaminosis D in the study subjects was not evaluated.  
 The patients were not followed up after Vitamin D supplementation and 
hence we could not assess the prognosis. 
 The etiology for MI in the young patients was not studied and so we could 
not rule out other confounding factors  
 
IMPLICATIONS FOR FUTURE 
 Routine estimation of serum vitamin D levels need be done in those with 
CAD, diabetes, hypertension and other risk factors because early detection 
and treatment of deficiency states has proven beneficial effects on mortality 
and morbidity. 
 Diabetic and hypertensive patients with low Vitamin D levels should be 
carefully monitored for CAD and other vascular events. 
 Obese individuals and those with dyslipidemia should also have routine 
estimations of serum Vitamin D. 
 India is a developing country with high prevalence of CAD in both urban 
and rural populations where poverty and illiteracy dominate. It is necessary 
to implement public health awareness programs and food fortification 
programs to overcome this deficit. 
 Fortification of foods such as milk and dairy products with Vitamin D has 
already been initiated in many developed countries and such food 
fortification programs are the need of the hour in our country. This is a very 
efficient method to reduce the incidence of Vitamin D deficiency especially 
in those on a purely vegetarian diet. 
 
  
 
 
CONCLUSION 
CONCLUSION 
 Vitamin D deficiency is associated with a wide variety of diseases, each of 
which poses a great burden on the community. The discovery of the causal 
association of Vitamin D deficiency in cardiovascular diseases is indeed an 
important breakthrough.  
 In our study, Serum Vitamin D levels were significantly lower in patients 
with acute Myocardial Infarction.  
 Our results add to the growing body of evidence suggesting that low 
Vitamin D levels may be an independent and potentially modiﬁable 
cardiovascular risk factor. 
 These findings may have potentially broad public health implications, given 
the high prevalence of Vitamin D deficiency in our country and the 
contribution of lifestyle and geography to Vitamin D status.  
 Vitamin D deficiency is a risk factor that can be easily measured and 
corrected. The treatment is safe and cost effective. Hence, general awareness 
needs to created on the early detection and management of this risk factor 
and guidelines need to be implemented. 
 
 Simple preventive measures like adequate sun exposure and food 
fortification can show a significant reduction in adverse cardiovascular 
events and other disease states associated with Vitamin D deficiency. 
 Large scale prospective randomized control trials are needed to further 
analyze the role of Vitamin D deficiency in coronary artery disease and to 
study the effects of Vitamin D supplementation on the prognosis and 
prevention of Coronary Artery Diseases. 
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURES 
 
DATA COLLECTION FORM 
 
 NAME : 
  AGE : 
 SEX : 
 OCCUPATION : 
 ADDRESS : 
 
      HISTORY 
 CHEST PAIN , PALPITATIONS , BREATHLESSNESS , GIDDINESS , 
SYNCOPE , FATIGUE  - DURATION, ONSET , PROGRESSION 
 
       PAST HISTORY  
 DIABETES MELLITUS , SYSTEMIC HYPERTENSION, 
CARDIOVASCULAR DISEASE , CEREBROVASCULAR DISEASE , 
PERIPHERAL VASCULAR DISEASE 
 
       PERSONAL HISTORY  
 ALCOHOL -  AMOUNT, FREQUENCY, DURATION 
 SMOKING - BEEDI/CIGARETTE, NUMBER/DAY, DURATION 
 
      DRUG HISTORY  
• VITAMIN D SUPPLEMENTATION 
• ANTI DIABETIC , ANTI  HYPERTENSIVE MEDICATIONS , CARDIAC 
DRUGS  
• DRUGS AFFECTING VITAMIN D METABOLISM  
       EXAMINATION 
 GENERAL EXAMINATION: 
  PALLOR , ICTERUS , CYANOSIS , CLUBBING , PEDAL 
EDEMA , 
LYMPHADENOPATHY 
 HEIGHT , WEIGHT , BODY MASS INDEX 
 VITAL SIGNS :   
 PULSE RATE 
 BLOOD PRESSURE 
 RESPIRATORY RATE 
 TEMPERATURE 
 
 SYSTEMIC EXAMINATION :  
 CARDIOVASCULAR SYSTEM  
 RESPIRATORY SYSTEM 
 ABDOMEN 
 CENTRAL NERVOUS SYSTEM 
    
    INVESTIGATIONS 
 
 COMPLETE BLOOD COUNT 
 BLOOD SUGAR 
 RENAL FUNCTION TESTS – UREA , CREATININE 
 LIPID PROFILE 
 SERUM ALBUMIN 
 SERUM BILIRUBIN 
 ECG 
 X-RAY CHEST             
 ECHO 
 SERUM 25(OH) VITAMIN D levels 
ABBREVIATIONS 
 
25(OH)D  – 25 Hydroxy Vitamin D 
1,25(OH)₂D  – 1,25 DiHydroxy Vitamin D 
Alb    – Albumin  
Apo    -  Apolipoprotein 
ATT    –  Anti Tuberculosis Treatment 
AWMI   –  Anterior Wall Myocardial Infarction   
BMD   –  Bone Mineral Density 
BMI    –  Body Mass Index 
CABG   –  Coronary Artery Bypass Grafting 
CAD    –  Coronary Artery Disease 
cAMP   –  cyclic adenosine monophosphate  
CD    –  Cluster of Differentiation 
CHD    –  Coronary Heart Disease 
CVD    –  Cardiovascular Disease  
DBP    –  Diastolic Blood Pressure 
ECG    –  Electrocardiograph 
FGF    –  Fibroblast Growth Factor 
IL    - Interleukin 
IOM    –  Institute of Medicine 
IU    – International Units 
IW/PWMI   – Inferior Wall / Posterior Wall Myocardial  
    Infarction    
LBBB   – Left Bundle Branch Block 
MI    – Myocardial Infarction 
MED    – Minimal Erythema Dose  
MMP   – Matrix Metalloproteinase 
NCD    – Non Communicable Disease 
NHANES   - The National Health and Nutritional     
  Examination Surveys  
PAR    - Population Attributable Risk 
PCI    – Percutaneous Coronary Intervention 
PTH    – Parathyroid Hormone  
RVMI   – Right Ventricular Myocardial Infarction 
S.Alb.   – Serum Albumin 
SBP    – Systolic Blood Pressure 
TB    – Tuberculosis  
T.Chol.   – Total Cholesterol 
TGF    – Transforming Growth Factor  
TGL    – Triglycerides 
TH2    – Type 2 Helper T  
TNF    – Tumor Necrosis Factor 
UVB    – Ultraviolet B 
VDD    – Vitamin D Deficiency 
VDR    – Vitamin D Receptor  
WBC   – White Blood Cells 
                                  
PARTICIPANT CONSENT FORM 
 
Participant‟s name:                                            Address: 
 
TITLE OF THE PROJECT: A STUDY ON SERUM VITAMIN D LEVELS 
IN ACUTE CORONARY SYNDROME. 
 
 
                   The details of the study have been provided to me in writing and 
explained to me in my own language. I confirm that I have understood the above 
study and had the opportunity to ask questions. I understand that my participation 
in the study is voluntary and that I am free to withdraw at any time, without giving 
any reason, without the medical care that will normally be provided by the hospital 
being affected. I agree not to restrict the use of any data or results that arise from 
this study provided such a use is only for scientific purpose(s). I have been given 
an information sheet giving details of the study. I fully consent to participate in the 
above study.  
 
 
 
 
Signature of the participant: ______________________ 
 
 
Date: _____________ 
 
  
 
 
MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
CASES 
No.     Name Age/Sex     STEMI Smoker    BMI     SBP    DBP    RBS  S.Alb.  T.Chol.    TGL VIT.D       Calcium 
1 Jeyakumar 26/M     AWMI       + 31.24 130 80 120 3.5 190 60 10.09 8.53 
2 Selvaraj 74/M   IW/RVMI      ---- 26.67 100 70 109 3.8 192 109 27.39 8.94 
3 Suresh 27/M     AWMI       + 21.34 116 74 113 4.2 200 165 8.26 9.17 
4 Arumugam 57/M     AWMI       + 24.91 130 80 97 3.5 173 135 19.32 8.9 
5 Sahul Hameed 46/M     ALMI       + 24.77 124 74 70 3 165 110 11.88 9.76 
6 Deenadayalan 60/M     AWMI       + 30.52 120 86 85 3.5 173 135 7.28 8.2 
7 Dorairaj 58/M     AWMI       + 24.69 110 70 78 3.8 151 96 18.2 9.4 
8 Ravi 53/M     AWMI       + 28.85 116 70 100 3.6 192 115 11.08 8.5 
9 Palani 43/M     IWMI      ---- 21.26 108 70 112 3.8 162 160 28.32 10.9 
10 Chelladurai 33/M     IWMI       + 23.05 120 80 90 3.5 245 154 8.94 9.2 
11 Sambanthan 59/M     AWMI       + 29.43 120 80 92 3.5 220 120 14.86 10.03 
12 Sriramulu 70/M IW/PWMI       + 29.52 118 76 78 4 275 110 21.71 9.6 
13 Mary 60/F     AWMI     ---- 29.3 140 80 85 3.5 290 174 14.1 8.43 
14 ArivudaiNambi 43/M     IWMI       + 30.78 136 86 96 3.3 285 127 10.35 8.29 
15 Ismail 42/M     AWMI       + 31.56 120 84 92 4.2 210 87 7.91 8.61 
16 Mary 65/F     AWMI     ---- 32.89 136 76 72 3.5 245 210 12.21 9.45 
17 Palani 60/M     AWMI       + 27.67 120 80 86 3 215 198 9.68 8.4 
18 Swaminathan 62/M  IW/PWMI     ---- 29.9 118 60 111 3.5 219 201 24.39 10.55 
19 Subramani 80/M      AWMI     ---- 20.05 100 80 89 2.8 195 150 14.08 9.16 
20 Babu 42/M     AWMI       + 34.5 120 80 101 3.5 180 135 15.96 9.2 
21 Rajkumar 50/M     AWMI       + 31.87 114 76 117 3.8 172 135 7.93 8.19 
22 Jeganathan 40/M     AWMI       + 30.08 120 80 77 3.5 264 208 15.77 9.14 
23 Chandran 65/M     AWMI     ---- 23.34 120 86 80 4.5 192 163 16.2 8.76 
24 Iqbal Basha 50/M     AWMI       + 27.56 116 70 79 3.3 166 140 18.12 8.8 
25 Kathirvel 50/M     AWMI       + 27.81 140 80 106 3.5 197 158 10.92 8.2 
26 Sekar 67/M IW/PWMI       + 24.52 90 70 76 4.2 210 183 7.6 7.9 
27 Lakshmi 70/F     AWMI     ---- 29.9 100 70 92 3.5 188 148 9.23 8.9 
28 Paramasivam 53/M     AWMI       + 28.03 120 80 98 3.8 187 145 13.87 8.44 
29 Palani 62/M IW/RVMI       + 21.89 110 70 124 4.5 193 200 12.11 9.2 
30 Muthukumar 49/M     AWMI       + 32.15 130 86 110 3.5 239 136 6.57 8.83 
31 Velu 30/M     AWMI       + 27.82 110 80 90 5.5 234 128 10.97 7.81 
32 Sekar 45/M     IWMI       + 27.8 100 76 78 3.5 239 136 7.19 9.2 
33 Dhanavel 67/M     AWMI       + 25.92 120 86 96 3.2 198 109 13.15 8.65 
34 Koti 56/M     AWMI       + 30.05 116 70 109 4.2 171 139 9.38 9.76 
35 Md. Saif 50/M     AWMI       + 22.87 124 80 110 3.8 226 246 20.6 8.22 
36 Bala 40/M IW/PWMI       + 20.14 110 70 74 3.5 206 236 10.3 9.78 
37 Perumal 65/M     AWMI       + 22.43 120 80 85 4.2 221 236 15.76 8.68 
38 Mala 60/F     AWMI     ---- 24.78 110 70 93 3.5 192 158 15.1 8.3 
  39  Sahira Banu 55/F     AWMI       + 25.5 100 60 102 3.6 187 140 9.79 9.27 
40 Kali 62/M     IWMI       + 23.73 90 60 98 3.8 210 225 7.62 10.17 
41 Babu 42/M     AWMI       + 24.19 128 70 78 3.5 185 106 11.23 8.2 
42 Md. Talip 55/M     AWMI       + 20.95 126 70 108 3.5 210 124 16.17 8.9 
43 Basha 59/M     AWMI      ---- 24.91 110 80 110 4.5 220 145 20.14 9.13 
44 Vincent 49/M     AWMI       + 23.5 120 76 78 3.5 232 228 18.94 8.34 
45 Murugan 32/M     AWMI       + 28.73 130 70 90 5.5 242 187 10.03 7.46 
46 Srikanth 29/M     ALMI      ---- 32.3 128 70 65 4.2 238 204 9.56 8.2 
47 Dhansekar 58/M     AWMI       + 23.17 116 80 92 3.5 230 224 21.09 10.19 
48 Munusamy 45/M     AWMI      ---- 25.67 100 60 84 3.8 239 198 15.43 9.76 
49 Hariharan 42/M     IWMI       + 29.78 90 70 78 5.5 199 149 8.47 7.79 
50 Pratap 29/M     AWMI       + 26.56 110 70 89 3.5 185 160 9.22 8.5 
    
 
CONTROLS 
No.     Name Age/Sex  Smoker    BMI     SBP    DBP    RBS  S.Alb.  T.Chol.       TGL VIT.D  Calcium 
1 Nataraj 67/M     ---- 25.09 110 80 89 3.8 153 
105 
16.47 10.06 
2 Ravikumar 40/M       + 23.07 120 80 92 3.5 158 
111 
20.02 9.22 
3 Jayaraman 40/M       + 23.45 120 80 95 3.5 162 
93 
30.8 8.5 
4 Ganesh 35/M       + 24.15 128 76 78 4.2 152 
103 
23.29 9.78 
5 Sivaraman 46/M       + 26.89 130 80 72 3.5 210 
144 
13.41 8.34 
6 Govindsamy 52/M       + 22.51 110 76 80 3 170 
110 
69.23 8.92 
7 Kandamani 60/F     ---- 22.92 100 70 102 3.5 161 
101 
15.17 9.72 
8 Mani 65/M     ---- 23.34 100 60 116 4.2 184 
138 
25.26 8.16 
9 Pachiannan 55/M       + 19.87 130 80 91 3.5 165 
96 
27.38 9.87 
10 Moorthy 42/M       + 21.34 120 80 105 5.5 169 
119 
9.18 9.42 
11 Chandran 35/M     ---- 24.22 118 70 72 2.8 176 
112 
20.7 8.28 
12 Sardar 55/M       + 20.08 120 80 90 3.5 163 
105 
19.77 8.16 
13 Abdul 60/M       + 30.87 118 76 97 3.2 156 
99 
15.2 8.9 
14 Bhaskar 52/M     ---- 25.56 120 70 80 3.5 197 
117 
33.06 8.12 
15 Ellappan 74/M     ---- 27.8 100 70 69 3.3 175 
98 
35.43 10.22 
16 Kumar 52/M       + 29.49 110 70 76 3.5 168 
92 
10.03 9.56 
17 Pandian 55/M       + 30.21 130 76 85 3.8 173 
93 
13.23 9.78 
18 Sivakumar 52/M       + 27.68 126 70 120 3.5 200 
120 
9.83 8.34 
 19 Mani 52/M     ---- 26.22 120 80 75 3.5 179 
120 
13.19 9.42 
20 Kanniappan 48/M       + 21.34 130 70 97 5.2 182 
103 
18.66 8.72 
21  Muthusamy 75/M     ----    23.8     110 70 86 3.5 164 
108 
23.37 8.36 
22 Mariappan 60/M       + 24.49 100 60 92 3.5 180 
223 
11.5 9.7 
23 Gangaiyan 70/M     ---- 21.37 100 70 107 5.5 186 
235 
19.66 9.45 
24 Vasu 40/M       + 26.67 120 80 88 3.5 192 
135 
20.17 8.62 
25 Manohar 48/M       + 27.93 120 70 106 3.5 188 
251 
43.62 8.4 
26 Srinivas 46/M     ---- 22.92 110 70 99 3.8 198 
142 
10.15 8.62 
27 Meena 51/F     ---- 24.56 110 76 113 3.5 186 
213 
16.06 9.27 
28 Subramani 58/M     ---- 19.87 120 80 85 3.2 179 
139 
10.79 10.08 
29 Meera 52/F     ---- 23.47 130 86 82 3.5 191 
246 
8.22 9.1 
30 James 52/M       + 21.9 130 80 94 4.5 177 
222 
51.7 8.8 
31 Vanaraj 60/M       + 23.5 118 70 126 3.5 170 
124 
8.56 8.3 
32 Kamaraj 34/M       + 22.89 120 70 100 2.8 204 
154 
29.33 8.72 
33 Pitchai 70/M       + 21.16 126 80 80 3.5 181 
240 
36.78 8.92 
34 Manickam 55/M       + 20.86 130 80 67 3.5 218 
170 
28.14 9.17 
35 Surendar 42/M       + 25.54 100 80 84 4.2 173 
230 
28.5 10.22 
36 Sarada 62/F       + 22.68 120 70 102 3.5 152 
105 
18.78 8.67 
37 Ponraj 48/M       + 22.71 110 70 90 5.2 168 
115 
34.89 9.82 
38 Raman 45/M       + 23.34 110 78 68 3.5 158 
96 
26.73 8.92 
39 Latha 50/F       + 26.12 120 80 82 5.2 210 
282 
41.7 8.64 
40 Ganesh 55/M       + 23.53 120 76 105 3.5 187 
123 
35.6 9.72 
41 Dilli Babu 60/M       + 28.12 126 76 67 4.8 220 
274 
12.8 8.47 
42 Chinnasamy 62/M       + 30.09 110 70 120 3.5 194 
150 
20.93 9.22 
43 Kolandaivel 51/M       + 25.2 100 60 130 4.2 185 
110 
23.45 9.13 
44 Kalyan 48/M     ---- 24.76 120 80 116 3.5 192 
178 
39.88 8.7 
45 Vijaykumar 34/M       + 23.45 120 78 72 3.8 189 
262 
42.56 8.9 
46 Noor 40/F     ---- 24.9 130 80 99 4.5 228 
159 
21.67 9.61 
47 Sampath 56/M       + 26.57 126 70 106 3.5 230 
128 
8.93 8.6 
48 Shankar 30/M       + 28.85 110 86 110 5.5 226 
235 
16.72 10.32 
49 Jayavendan 59/M       + 20.43 108 70 80 3.5 172 
140 
19.87 9.43 
50 Rajesh 40/M     ---- 27.3 110 70 92 3.5 168 
259 
21.31 9.21 
 
 
 
 
 
